The U.S.Food and Drug Administration (FDA) is anticipated to approve a novel injection for HIV prevention later this month.

The injection, lenacapavir, administered twice annually, represents a perhaps significant advancement in combating HIV.

Gilead sciences conducted trials of the shot involving women and girls, with none of the participants who received the injections contracting HIV.

this initial success contributed to a 73% increase in Gilead’s stock value over the past year, according to The Wall Street Journal.

“We no it’s challenging to take a daily pill for prevention,and we see an incredible prospect here,” said Johanna Mercier,Gilead’s chief commercial officer.

Currently, over 400,000 individuals in the United States utilize pills for HIV pre-exposure prophylaxis, as reported by The Wall Street Journal.

Gilead projects that the number of users will exceed 1 million within the next decade.

Many individuals have expressed a preference for injections over daily pills. A survey of over 500 PrEP users revealed that 95% woudl opt for a long-acting injection.

Sales of alternative long-acting options, such as Apretude from GSK, have experienced considerable growth, increasing by 63% in the past year.

Challenges and Opportunities

Despite promising results, Gilead faces several obstacles.

“we know it’s challenging to take a daily pill for prevention, and we see an incredible opportunity here,”

One challenge involves reaching the populations most in need of PrEP. Black Americans account for 39% of new HIV cases but only 14% of current PrEP users.

Stigma and inadequate insurance coverage continue to limit access for many individuals.

Gilead has stated that reaching underserved communities is a primary objective. While most current PrEP users have commercial insurance, Medicaid will be crucial for expanding access to lower-income populations.

Some experts are concerned that the new injection may simply supplant existing Gilead products, such as the daily pill Descovy, which currently holds approximately 40% to 45% of the market.

though, Gilead anticipates that the injection will contribute to an overall increase in the number of individuals utilizing PrEP, both domestically and internationally.

“We’re thinking globally about the public health impact we can have,” Mercier said.

The company is collaborating with governments and health organizations in the U.K. and low-income countries to enhance awareness and accessibility of these products.